X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (750) 750
Newspaper Article (51) 51
Publication (16) 16
Book Review (10) 10
Magazine Article (8) 8
Trade Publication Article (4) 4
Book Chapter (2) 2
Book / eBook (1) 1
Dissertation (1) 1
Reference (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (360) 360
male (231) 231
female (224) 224
middle aged (200) 200
risk factors (159) 159
diabetes (155) 155
aged (154) 154
endocrinology & metabolism (145) 145
cardiac & cardiovascular systems (123) 123
type 2 diabetes (110) 110
adult (103) 103
cardiovascular disease (95) 95
treatment outcome (92) 92
diabetes mellitus, type 2 - drug therapy (87) 87
diabetes mellitus (86) 86
cholesterol (84) 84
cardiovascular diseases (78) 78
abridged index medicus (77) 77
risk (74) 74
research (70) 70
cardiovascular (69) 69
cardiovascular diseases - prevention & control (68) 68
medicine, general & internal (68) 68
double-blind method (64) 64
diabetes mellitus, type 2 - complications (62) 62
coronary-heart-disease (61) 61
prevention (61) 61
hypoglycemic agents - therapeutic use (57) 57
analysis (56) 56
canada (55) 55
diabetes mellitus, type 2 - blood (55) 55
cardiovascular-disease (54) 54
care and treatment (54) 54
drug therapy (54) 54
blood pressure (52) 52
clinical trials (52) 52
insulin (52) 52
cholesterol, ldl - blood (50) 50
health aspects (50) 50
mortality (50) 50
lipids (49) 49
glucose (48) 48
hypertension (47) 47
glycemic control (46) 46
management (42) 42
peripheral vascular disease (42) 42
statins (41) 41
nutrition & dietetics (40) 40
risk assessment (40) 40
disease (39) 39
cardiovascular diseases - etiology (38) 38
cardiovascular diseases - epidemiology (37) 37
diet (37) 37
hydroxymethylglutaryl-coa reductase inhibitors - therapeutic use (37) 37
time factors (37) 37
blood glucose - metabolism (36) 36
myocardial-infarction (35) 35
blood-pressure (34) 34
atherosclerosis (33) 33
drug therapy, combination (33) 33
follow-up studies (33) 33
guidelines (33) 33
other (33) 33
practice guidelines as topic (33) 33
safety (33) 33
anticholesteremic agents - therapeutic use (32) 32
dose-response relationship, drug (32) 32
evidence-based medicine (32) 32
hypercholesterolemia (32) 32
obesity (32) 32
randomized controlled trials as topic (32) 32
hypolipidemic agents - therapeutic use (31) 31
blood glucose - drug effects (30) 30
dosage and administration (30) 30
lipoproteins (30) 30
mellitus (30) 30
risk-factors (30) 30
antihypertensive agents - therapeutic use (29) 29
cholesterol, hdl - blood (29) 29
diabetes mellitus, type 2 - epidemiology (29) 29
body weight (28) 28
myocardial infarction (28) 28
animals (27) 27
canada - epidemiology (27) 27
events (27) 27
low density lipoproteins (27) 27
efficacy (26) 26
outcomes (26) 26
patient outcomes (26) 26
patients (26) 26
atorvastatin (25) 25
dyslipidemia (25) 25
glycated hemoglobin a - metabolism (25) 25
meta-analysis (25) 25
metaanalysis (25) 25
stroke (25) 25
studies (25) 25
therapy (25) 25
association (24) 24
complications and side effects (24) 24
more...
Library Location Library Location
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Journal Article
The New England journal of medicine, ISSN 1533-4406, 2012, Volume 367, Issue 22, pp. 2089 - 2099
Dalcetrapib, an inhibitor of cholesteryl ester transfer protein, raises HDL cholesterol levels. In this clinical trial involving patients with an acute... 
TRIAL | MEDICINE, GENERAL & INTERNAL | HEART-DISEASE | CARDIOVASCULAR EVENTS | STATIN THERAPY | SAFETY | HIGH-RISK | CHOLESTEROL EFFLUX | PREVENTION | HDL CHOLESTEROL | HIGH-DENSITY-LIPOPROTEIN | Cholesterol Ester Transfer Proteins - antagonists & inhibitors | Cardiovascular Diseases - prevention & control | Humans | Middle Aged | Male | Risk | Secondary Prevention | Biomarkers - blood | Apolipoproteins - blood | Anticholesteremic Agents - adverse effects | Acute Coronary Syndrome - drug therapy | Sulfhydryl Compounds - adverse effects | Anticholesteremic Agents - therapeutic use | Triglycerides - blood | Cardiovascular Diseases - mortality | Cholesterol, HDL - blood | Cholesterol, LDL - blood | Female | Aged | Blood Pressure - drug effects | Sulfhydryl Compounds - therapeutic use | C-Reactive Protein - analysis | Measurement | Cholesterol, HDL | Patient outcomes | Dosage and administration | Research | Acute coronary syndrome | Drug therapy | Health aspects | Cardiovascular agents | Myocardial infarction | Cerebral infarction | Lipoproteins (low density) | Stroke | C-reactive protein | Heart attacks | Mortality | Cardiovascular disease | Angina | Coronary artery disease | Cholesterol | Cholesteryl ester transfer protein | Studies | Ischemia | Diet | Biomarkers | Blood pressure | Acute coronary syndromes | Cardiovascular diseases | Heart diseases | Lipoproteins (high density)
Journal Article
The New England journal of medicine, ISSN 1533-4406, 2016, Volume 374, Issue 21, pp. 2021 - 2031
Journal Article
The New England journal of medicine, ISSN 1533-4406, 2016, Volume 375, Issue 19, pp. 1834 - 1844
Journal Article
The New England journal of medicine, ISSN 1533-4406, 2019, Volume 381, Issue 14, pp. 1309 - 1320
Patients with stable coronary artery disease and diabetes were randomly assigned to receive either ticagrelor plus aspirin or placebo plus aspirin. At 40... 
MEDICINE, GENERAL & INTERNAL | CLOPIDOGREL | DUAL ANTIPLATELET THERAPY | MYOCARDIAL-INFARCTION | CARDIOVASCULAR EVENTS | CLINICAL BENEFIT | PLATELET INHIBITION | PRASUGREL | COLLABORATIVE METAANALYSIS | SECONDARY PREVENTION | 60 MG | Myocardial Infarction - epidemiology | Follow-Up Studies | Humans | Middle Aged | Hemorrhage - mortality | Male | Incidence | Drug Therapy, Combination - adverse effects | Ticagrelor - adverse effects | Aspirin - adverse effects | Female | Stroke - epidemiology | Aspirin - therapeutic use | Platelet Aggregation Inhibitors - therapeutic use | Ticagrelor - therapeutic use | Diabetes Mellitus, Type 2 - complications | Platelet Aggregation Inhibitors - adverse effects | Stroke - prevention & control | Double-Blind Method | Hemorrhage - epidemiology | Kaplan-Meier Estimate | Treatment Outcome | Coronary Artery Disease - drug therapy | Coronary Artery Disease - mortality | Coronary Artery Disease - complications | Diabetes Mellitus, Type 2 - mortality | Aged | Myocardial Infarction - prevention & control | Hemorrhage - chemically induced | Diabetes Mellitus, Type 2 - drug therapy | Control | Usage | Safety and security measures | Diabetes | Cardiovascular diseases | Drug therapy | Ticagrelor | Coronary heart disease | Myocardial infarction | Cerebral infarction | Aspirin | Stroke | Heart attacks | Diabetes mellitus | Coronary artery | Cardiovascular disease | Thrombosis | Hemorrhage | Thrombolysis | Bleeding | Design | Ischemia | Blood platelets | Coronary vessels | Population | Diabetes mellitus (non-insulin dependent) | Heart diseases | Research centers | Life Sciences | Human health and pathology
Journal Article
The New England journal of medicine, ISSN 1533-4406, 2017, Volume 376, Issue 15, pp. 1430 - 1440
Journal Article
Diabetes Research and Clinical Practice, ISSN 0168-8227, 2016, Volume 120, pp. S122 - S122
Journal Article
Diabetes care, ISSN 1935-5548, 2017, Volume 41, Issue 1, pp. 14 - 31
Journal Article
The New England journal of medicine, ISSN 1533-4406, 2016, Volume 374, Issue 21, pp. 2009 - 2020
Journal Article